Fundamental Data for AUXL

AUXILIUM P(NSDQ:AUXL)

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie''s Disease that may also prove useful for the treatment of Dupuytren''s Disease.

# Employees: 340

Address: 40 Valley Stream Parkway,Malvern,PA,USA

Phone: 484 321-5900

Fax: 484 321-5999

Website: www.auxilium.com

Email:

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Rolf A. Classon (Chmn.)

Armando Anido (Presi.; C.E.O.; Dir.)

James E. Fickenscher (C.F.O.; Prin. Acctg. Off.)

Al Altomari (Dir.)

Edwin A. Bescherer Jr. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/17/2010

Mean EPS (Next Qtr): ($0.31)

Mean EPS (Year): ($1.29)

Mean Estimate(Long Term): $30.00

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 15

Shares Performance

Period	AUXL	Compare to S&P
YTD	21.83 %	0.82 %
4 Weeks	10.14 %	4.56 %
12 Weeks	17.42 %	9.34 %

Shares Information

Analyst Coverage: Y

Avg Volume: 267541

Shares Outstanding: 45M

Market Cap: $1.59B

52 Week High: $36.63

52 Week Low: $19.01

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 AUXL split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: -9.38 %

EPS Growth in Last Year: -45.83 %

Sales Growth in Last Quarter: 7.52 %

Sales Growth in Last Quarter: 29.33 %

Financials

Qtr Book Value: $12.61

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 10.520